The 36-month beta value for NKTR is at 0.59. Analysts have varying views on the stock, with 2 analysts rating it as a “buy,” 2 rating it as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for NKTR is 177.74M, and currently, shorts hold a 2.45% of that float. The average trading volume for NKTR on January 24, 2025 was 1.83M shares.
NKTR) stock’s latest price update
Nektar Therapeutics (NASDAQ: NKTR) has experienced a decline in its stock price by -2.55 compared to its previous closing price of 0.92. However, the company has seen a fall of -1.18% in its stock price over the last five trading days. prnewswire.com reported 2025-01-10 that SAN FRANCISCO, Jan. 10, 2025 /PRNewswire/ — Nektar Therapeutics (Nasdaq: NKTR) today announced the company has completed target enrollment in its REZOLVE-AD Phase 2b study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis. Rezpegaldesleukin is a first-in-class interleukin-2 receptor (IL-2R) agonist that proliferates and activates regulatory T cells (Tregs) with promising dose-dependent clinical activity in multiple skin disease settings.
NKTR’s Market Performance
NKTR’s stock has fallen by -1.18% in the past week, with a monthly drop of -4.93% and a quarterly drop of -35.64%. The volatility ratio for the week is 7.13% while the volatility levels for the last 30 days are 8.24% for Nektar Therapeutics. The simple moving average for the past 20 days is -7.97% for NKTR’s stock, with a -29.39% simple moving average for the past 200 days.
Analysts’ Opinion of NKTR
Many brokerage firms have already submitted their reports for NKTR stocks, with B. Riley Securities repeating the rating for NKTR by listing it as a “Buy.” The predicted price for NKTR in the upcoming period, according to B. Riley Securities is $4 based on the research report published on January 08, 2025 of the current year 2025.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see NKTR reach a price target of $6.50. The rating they have provided for NKTR stocks is “Buy” according to the report published on December 10th, 2024.
Piper Sandler gave a rating of “Overweight” to NKTR, setting the target price at $7 in the report published on November 04th of the previous year.
NKTR Trading at -13.61% from the 50-Day Moving Average
After a stumble in the market that brought NKTR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -53.60% of loss for the given period.
Volatility was left at 8.24%, however, over the last 30 days, the volatility rate increased by 7.13%, as shares sank -3.63% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -34.70% lower at present.
During the last 5 trading sessions, NKTR fell by -1.18%, which changed the moving average for the period of 200-days by -32.23% in comparison to the 20-day moving average, which settled at $0.9720. In addition, Nektar Therapeutics saw -3.81% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NKTR starting from Wilson Mark Andrew, who sale 33,402 shares at the price of $0.90 back on Dec 23 ’24. After this action, Wilson Mark Andrew now owns 351,892 shares of Nektar Therapeutics, valued at $30,062 using the latest closing price.
Wilson Mark Andrew, the Chief Legal Officer of Nektar Therapeutics, sale 16,560 shares at $0.89 during a trade that took place back on Dec 24 ’24, which means that Wilson Mark Andrew is holding 335,332 shares at $14,738 based on the most recent closing price.
Stock Fundamentals for NKTR
Current profitability levels for the company are sitting at:
- -1.46 for the present operating margin
- 0.68 for the gross margin
The net margin for Nektar Therapeutics stands at -1.81. The total capital return value is set at -0.57. Equity return is now at value -161.63, with -44.87 for asset returns.
Based on Nektar Therapeutics (NKTR), the company’s capital structure generated 0.69 points at debt to capital in total, while cash flow to debt ratio is standing at -1.63. The debt to equity ratio resting at 2.21. The interest coverage ratio of the stock is -5.48.
Currently, EBITDA for the company is -243.11 million with net debt to EBITDA at -0.55. When we switch over and look at the enterprise to sales, we see a ratio of 2.61. The receivables turnover for the company is 43.87for trailing twelve months and the total asset turnover is 0.3. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.24.
Conclusion
In conclusion, Nektar Therapeutics (NKTR) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
